CureVac (NASDAQ:CVAC) Trading 9.9% Higher

Shares of CureVac (NASDAQ:CVAC) were up 9.9% on Monday . The stock traded as high as $3.01 and last traded at $3.01. Approximately 307,717 shares changed hands during mid-day trading, a decline of 68% from the average daily volume of 953,040 shares. The stock had previously closed at $2.74.

Analysts Set New Price Targets

Separately, JMP Securities lowered their price target on CureVac from $18.00 to $16.00 and set a “market outperform” rating on the stock in a report on Friday, August 16th.

CureVac Trading Down 0.7 %

The company has a debt-to-equity ratio of 0.09, a current ratio of 2.29 and a quick ratio of 2.28. The company has a market cap of $678.36 million, a P/E ratio of -2.29, a P/E/G ratio of 1.94 and a beta of 2.62. The stock’s 50-day moving average is $3.32 and its two-hundred day moving average is $3.29.

CureVac (NASDAQ:CVAC) last released its quarterly earnings results on Thursday, August 15th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.06). CureVac had a negative net margin of 422.66% and a negative return on equity of 57.18%. The firm had revenue of $15.55 million for the quarter, compared to the consensus estimate of $10.07 million. As a group, equities research analysts predict that CureVac will post 0.05 earnings per share for the current fiscal year.

Institutional Trading of CureVac

Large investors have recently added to or reduced their stakes in the business. Ballentine Partners LLC purchased a new position in shares of CureVac during the 1st quarter worth $38,000. Bank of New York Mellon Corp bought a new position in CureVac in the 2nd quarter worth $54,000. Vanguard Personalized Indexing Management LLC purchased a new position in CureVac during the fourth quarter valued at $68,000. Signaturefd LLC grew its holdings in CureVac by 232.0% during the second quarter. Signaturefd LLC now owns 22,043 shares of the company’s stock valued at $75,000 after purchasing an additional 15,403 shares during the period. Finally, Aristides Capital LLC purchased a new stake in CureVac in the fourth quarter worth about $100,000. 17.26% of the stock is currently owned by institutional investors.

CureVac Company Profile

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.